Board of Directors

Bruce L.A. Carter, Ph.D.
Chairman of the Board
Dr. Carter was appointed Chairman of the Board in April 2005. From April 1998 to January 2009, he served as Chief Executive Officer. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988 Novo Nordisk acquired ZymoGenetics and, in 1994, Dr. Carter was promoted to Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the then parent company of ZymoGenetics. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

James A. Harper
James A. Harper was appointed as a director in July 2004. Mr. Harper has thirty years of global marketing, operations and strategic experience in the pharmaceutical and medical device industries, and recently retired from the post of Group Vice President of Global Marketing and Sales at Eli Lilly and Company. Mr. Harper holds an M.B.A. from the Wharton School in Marketing/Finance and a B.A. from Vanderbilt University in Biology.

David I. Hirsh, Ph.D.
Dr. Hirsh has served as a director since November 2000. Dr. Hirsh is Executive Vice President of Research at Columbia University since September 2003. From 1990 to September 2003, he was the Robert Wood Johnson, Jr. Professor and Chairman of the Department of Biochemistry and Molecular Biophysics at the College of Physicians and Surgeons of Columbia University. From 1984 to 1990, he served as Executive Vice President of Research at Synergen, Inc., a biotechnology company. From 1971 to 1985, he served as a Professor at the University of Colorado. Dr. Hirsh received a B.A. in Biology from Reed College and a Ph.D. in Biochemistry from Rockefeller University.

Lars Fruergaard Jørgensen
Lars Fruergaard Jørgensen was appointed as a director in June 2010. He has served as Senior Vice President, Information Technology and Corporate Development of Novo Nordisk A/S since September 2004. From 2001 to 2004, he served as Vice President, Regional Finance and Information Technology of Novo Nordisk Pharmaceutical Ltd. with responsibility for a region comprising Japan and Oceania. He joined Novo Nordisk in 1991 and has held positions of increasing responsibility within the finance, accounting and administration departments. He currently serves, or has during the past five years served, as a director of NNIT A/S and as chairman of the board of Harno Invest A/S. Mr. Jørgensen received a B.Sc. and M.Sc. in Business Administration from the Århus Business School, Denmark.

Jonathan S. Leff
Mr. Leff has served as a director since November 2000. Since January 2000, Mr. Leff has served as a General Partner of Warburg, Pincus & Co., which is the Managing Partner of Warburg Pincus LLC, and as a Managing Director of Warburg Pincus LLC, a private equity investment firm. From January 1999 to December 1999, Mr. Leff served as a Vice President of Warburg Pincus LLC and as an Associate from July 1996 to December 1998. Mr. Leff received a B.A. in Government from Harvard College and an M.B.A. from Stanford University.

David H. MacCallum
Mr. MacCallum has served as a director since April 2005. Since 2002, Mr. MacCallum has served as the Managing Director of Outer Islands Capital, an investment fund specializing in health care investments. He served as Global Head of Health Care investment banking for Salomon Smith Barney and formed the Life Sciences group at UBS Securities, where he was Managing Director and Global Head of Life Sciences. Prior to that, Mr. MacCallum built the health care practice at Hambrecht & Quist, an investment banking firm, where he was Head of Health Care and Co-Head of Investment Banking. Mr. MacCallum received an A. B. degree from Brown University and an M.B.A. degree from New York University. He holds the Chartered Financial Analyst designation.

A. Bruce Montgomery, M.D.
A. Bruce Montgomery, M.D. was appointed as a director in 2010. He serves as Senior Vice President and Head of Respiratory Therapeutics at Gilead Sciences, Inc., where he was instrumental in helping to obtain approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Dr. Montgomery founded Corus Pharma in January 2001 and served as the company's CEO and Director for five years. Prior to founding Corus, Dr. Montgomery served as Executive Vice President of Research and Development at PathoGenesis Corporation, where he managed the development of inhaled tobramycin for the treatment of cystic fibrosis. Previously, Dr. Montgomery helped Genentech Inc. develop Pulmozyme, another treatment for cystic fibrosis. Dr. Montgomery received his Bachelor of Science in Chemistry and Doctorate of Medicine from the University of Washington, Seattle and is a board certified internist and pulmonologist.

Kurt Anker Nielsen
Mr. Nielsen has served as a director since June 1997. From December 2000 to September, 2003, when he retired, Mr. Nielsen served as Co-Chief Executive Officer of Novo A/S. Mr. Nielsen held numerous positions within the Novo Nordisk organization since joining Novo Nordisk in 1974, including Deputy Chief Executive Officer, Chief Financial Officer, Executive Vice President of Corporate Finance, Vice President of Corporate Planning and Communications, and Head of the Corporate Planning Department. Prior to joining Novo Nordisk, Mr. Nielsen served as a management consultant at Booz, Allen and Hamilton of Scandinavia. He also served as a business economist at Carlsberg A/S in Denmark. Mr. Nielsen received a B.A in Economics and an M.A. in Commerce from the Copenhagen Business School.

Edward E. Penhoet, Ph.D.
Dr. Penhoet has served as a director since May 2000. Dr. Penhoet serves as director of the Alta Biopharma Funds II, III, and VIII at Alta Partners, a venture capital firm. Dr. Penhoet is past President of the Gordon and Betty Moore Foundation, where he served since 2002 as Chief Program Officer, Science and Higher Education. He served as Dean of the School of Public Health at the University of California, Berkeley from July 1998 to July 2002. From May 1998 to February 2001, he served as Vice Chairman of the board of Chiron Corporation, a biotechnology company, which he co-founded in 1981. From 1981 to May 1998, he served as President, Chief Executive Officer and a director of Chiron. From 1971 to 1981, he was a faculty member in the Department of Biochemistry at the University of California, Berkeley. Dr. Penhoet received a B.A. in Biology from Stanford University and a Ph.D. in Biochemistry from the University of Washington.

Douglas E. Williams, Ph.D.
Dr. Williams currently serves as Chief Executive Officer of ZymoGenetics and as a member of the company's Board of Directors. He previously served as President from July 2007 to January 2009. He joined ZymoGenetics in 2004 as Chief Scientific Officer and Executive Vice President and was responsible for the company's research and development programs. Dr. Williams has held senior level positions at a number of notable biotechnology companies, including Seattle Genetics, Immunex, Amgen and Genesis Research and Development, a New Zealand based biotechnology company. As Executive Vice President and Chief Technology Officer at Immunex, Dr. Williams played a significant role in the discovery and early development of Enbrel, the first biologic approved for the treatment of rheumatoid arthritis. In addition, Dr. Williams was a member of Immunex Corporation's Board of Directors. Before entering the biotechnology industry, Dr. Williams served on the faculty of the Indiana University School of Medicine and worked in the Department of Laboratory Medicine at the Roswell Park Memorial Institute. Dr. Williams earned a B.S. magna cum laude in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo.